These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25148777)

  • 1. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
    Brown D; Müller M; Sehr P; Pawlita M; Seitz H; Rubio I; Antonello J; Radley D; Roberts C; Saah A
    Vaccine; 2014 Oct; 32(44):5880-7. PubMed ID: 25148777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
    Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
    Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.
    Roberts C; Green T; Hess E; Matys K; Brown MJ; Haupt RM; Luxembourg A; Vuocolo S; Saah A; Antonello J
    Hum Vaccin Immunother; 2014; 10(8):2168-74. PubMed ID: 25424920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 mo using a pseudovirion neutralization assay.
    Roberts C; Swoyer R; Bryan J
    Hum Vaccin Immunother; 2012 Apr; 8(4):431-4. PubMed ID: 22336880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
    Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
    Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.
    Kahn JA; Xu J; Kapogiannis BG; Sleasman JW
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):241-245. PubMed ID: 28291048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method.
    Toh ZQ; He L; Chen C; Huang A; Russell FM; Garland SM; Reyburn R; Ratu T; Tuivaga E; Frazer IH; Mulholland EK; Licciardi PV
    Front Immunol; 2020; 11():585768. PubMed ID: 33193410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.
    Nygård M; Saah A; Munk C; Tryggvadottir L; Enerly E; Hortlund M; Sigurdardottir LG; Vuocolo S; Kjaer SK; Dillner J
    Clin Vaccine Immunol; 2015 Aug; 22(8):943-8. PubMed ID: 26084514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Mei W; McNeil S; Money D; Dionne M; Karunakaran KP; Palefsky JM; Dobson S; Ogilvie G; Petric M
    Clin Vaccine Immunol; 2011 Mar; 18(3):418-23. PubMed ID: 21248158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies.
    Quang C; Chung AW; Kemp TJ; Ratu T; Tuivaga E; Russell FM; Licciardi PV; Toh ZQ
    J Med Virol; 2024 Jun; 96(6):e29732. PubMed ID: 38874202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
    Dessy FJ; Giannini SL; Bougelet CA; Kemp TJ; David MP; Poncelet SM; Pinto LA; Wettendorff MA
    Hum Vaccin; 2008; 4(6):425-34. PubMed ID: 18948732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18.
    Trevisan A; Wissing MD; Dagenais C; Forest P; Ramanakumar AV; Burchell AN; Franco EL; Coutlée F; Couillard M
    J Gen Virol; 2021 May; 102(5):. PubMed ID: 34043499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials.
    Safaeian M; Ghosh A; Porras C; Lin SW; Rodriguez AC; Schiffman M; Wacholder S; Kemp T; Gonzalez P; Wentzensen N; Esser M; Meuree A; Matys K; Quint W; van Doorn LJ; Sherman ME; Herrero R; Pinto LA; Hildesheim A
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1547-54. PubMed ID: 22752082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity correlation in cynomolgus monkeys between Luminex-based total IgG immunoassay and pseudovirion-based neutralization assay for a 14-valent recombinant human papillomavirus vaccine.
    Bei L; Zhang X; Meng D; Gao S; Jia J; Zhao D; Luo C; Li X; Qiu H; Xie L
    J Med Virol; 2022 Aug; 94(8):3946-3955. PubMed ID: 35388509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.
    Kemp TJ; Matsui K; Shelton G; Safaeian M; Pinto LA
    Hum Vaccin Immunother; 2015; 11(2):337-46. PubMed ID: 25695397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.